 | • レポートコード：GIR-23F3295 • 出版社/出版日：GlobalInfoResearch / 2023年2月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Human Granulocyte Colony-stimulating Factor Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界のヒト顆粒球コロニー刺激因子の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 ヒト顆粒球コロニー刺激因子市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・300μg/回、150μg/回、75μg/回、その他 アプリケーション別セグメントは次のように区分されます。 ・病院、診療所 世界のヒト顆粒球コロニー刺激因子市場の主要なマーケットプレーヤーは以下のとおりです。 ・Chugai Pharmaceutical、Kyowa Hakko Kirin、Sanway、GenSci、SL PHARM、Kexing Bioproducts、Qilu Pharmaceutical、CSPC、Wuzhong Pharmaceutical、Quangang Pharmaceutical、Huabei Pharmaceutical、Harbin Pharmaceutical、Amoytop Biotech、Jiuyuan Gene Engineering、Four Rings Biopharmaceutical 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - ヒト顆粒球コロニー刺激因子の概要 - タイプ別分析（2017年vs2021年vs2028年）：300μg/回、150μg/回、75μg/回、その他 - アプリケーション別分析（2017年vs2021年vs2028年）：病院、診療所 - 世界のヒト顆粒球コロニー刺激因子市場規模・予測 - 世界のヒト顆粒球コロニー刺激因子生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Chugai Pharmaceutical、Kyowa Hakko Kirin、Sanway、GenSci、SL PHARM、Kexing Bioproducts、Qilu Pharmaceutical、CSPC、Wuzhong Pharmaceutical、Quangang Pharmaceutical、Huabei Pharmaceutical、Harbin Pharmaceutical、Amoytop Biotech、Jiuyuan Gene Engineering、Four Rings Biopharmaceutical ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：300μg/回、150μg/回、75μg/回、その他 ・アプリケーション別分析2017年-2028年：病院、診療所 ・ヒト顆粒球コロニー刺激因子の北米市場分析 - ヒト顆粒球コロニー刺激因子の北米市場：タイプ別市場規模2017年-2028年 - ヒト顆粒球コロニー刺激因子の北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・ヒト顆粒球コロニー刺激因子のヨーロッパ市場分析 - ：ヒト顆粒球コロニー刺激因子のヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：ヒト顆粒球コロニー刺激因子のヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・ヒト顆粒球コロニー刺激因子のアジア太平洋市場分析 - ヒト顆粒球コロニー刺激因子のアジア太平洋市場：タイプ別市場規模2017年-2028年 - ヒト顆粒球コロニー刺激因子のアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・ヒト顆粒球コロニー刺激因子の南米市場分析 - ヒト顆粒球コロニー刺激因子の南米市場：タイプ別市場規模2017年-2028年 - ヒト顆粒球コロニー刺激因子の南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・ヒト顆粒球コロニー刺激因子の中東・アフリカ市場分析 - ヒト顆粒球コロニー刺激因子の中東・アフリカ市場：タイプ別市場規模2017年-2028年 - ヒト顆粒球コロニー刺激因子の中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Human Granulocyte Colony-stimulating Factor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Human Granulocyte Colony-stimulating Factor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Human Granulocyte Colony-stimulating Factor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 300μg/Dose segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Human Granulocyte Colony-stimulating Factor include Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway, GenSci, and SL PHARM, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Human Granulocyte Colony-stimulating Factor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
300μg/Dose
150μg/Dose
75μg/Dose
Others
Market segment by Application can be divided into
Hospital
Clinic
The key market players for global Human Granulocyte Colony-stimulating Factor market are listed below:
Chugai Pharmaceutical
Kyowa Hakko Kirin
Sanway
GenSci
SL PHARM
Kexing Bioproducts
Qilu Pharmaceutical
CSPC
Wuzhong Pharmaceutical
Quangang Pharmaceutical
Huabei Pharmaceutical
Harbin Pharmaceutical
Amoytop Biotech
Jiuyuan Gene Engineering
Four Rings Biopharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Granulocyte Colony-stimulating Factor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Human Granulocyte Colony-stimulating Factor, with price, sales, revenue and global market share of Human Granulocyte Colony-stimulating Factor from 2019 to 2022.
Chapter 3, the Human Granulocyte Colony-stimulating Factor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Granulocyte Colony-stimulating Factor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Human Granulocyte Colony-stimulating Factor market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Human Granulocyte Colony-stimulating Factor.
Chapter 13, 14, and 15, to describe Human Granulocyte Colony-stimulating Factor sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Human Granulocyte Colony-stimulating Factor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Human Granulocyte Colony-stimulating Factor Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 300μg/Dose
1.2.3 150μg/Dose
1.2.4 75μg/Dose
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Human Granulocyte Colony-stimulating Factor Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Human Granulocyte Colony-stimulating Factor Market Size & Forecast
1.4.1 Global Human Granulocyte Colony-stimulating Factor Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Human Granulocyte Colony-stimulating Factor Sales in Volume (2017-2028)
1.4.3 Global Human Granulocyte Colony-stimulating Factor Price (2017-2028)
1.5 Global Human Granulocyte Colony-stimulating Factor Production Capacity Analysis
1.5.1 Global Human Granulocyte Colony-stimulating Factor Total Production Capacity (2017-2028)
1.5.2 Global Human Granulocyte Colony-stimulating Factor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Human Granulocyte Colony-stimulating Factor Market Drivers
1.6.2 Human Granulocyte Colony-stimulating Factor Market Restraints
1.6.3 Human Granulocyte Colony-stimulating Factor Trends Analysis
2 Manufacturers Profiles
2.1 Chugai Pharmaceutical
2.1.1 Chugai Pharmaceutical Details
2.1.2 Chugai Pharmaceutical Major Business
2.1.3 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
2.1.4 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Kyowa Hakko Kirin
2.2.1 Kyowa Hakko Kirin Details
2.2.2 Kyowa Hakko Kirin Major Business
2.2.3 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Product and Services
2.2.4 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Sanway
2.3.1 Sanway Details
2.3.2 Sanway Major Business
2.3.3 Sanway Human Granulocyte Colony-stimulating Factor Product and Services
2.3.4 Sanway Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 GenSci
2.4.1 GenSci Details
2.4.2 GenSci Major Business
2.4.3 GenSci Human Granulocyte Colony-stimulating Factor Product and Services
2.4.4 GenSci Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 SL PHARM
2.5.1 SL PHARM Details
2.5.2 SL PHARM Major Business
2.5.3 SL PHARM Human Granulocyte Colony-stimulating Factor Product and Services
2.5.4 SL PHARM Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Kexing Bioproducts
2.6.1 Kexing Bioproducts Details
2.6.2 Kexing Bioproducts Major Business
2.6.3 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Product and Services
2.6.4 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Qilu Pharmaceutical
2.7.1 Qilu Pharmaceutical Details
2.7.2 Qilu Pharmaceutical Major Business
2.7.3 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
2.7.4 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 CSPC
2.8.1 CSPC Details
2.8.2 CSPC Major Business
2.8.3 CSPC Human Granulocyte Colony-stimulating Factor Product and Services
2.8.4 CSPC Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Wuzhong Pharmaceutical
2.9.1 Wuzhong Pharmaceutical Details
2.9.2 Wuzhong Pharmaceutical Major Business
2.9.3 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
2.9.4 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Quangang Pharmaceutical
2.10.1 Quangang Pharmaceutical Details
2.10.2 Quangang Pharmaceutical Major Business
2.10.3 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
2.10.4 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Huabei Pharmaceutical
2.11.1 Huabei Pharmaceutical Details
2.11.2 Huabei Pharmaceutical Major Business
2.11.3 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
2.11.4 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Harbin Pharmaceutical
2.12.1 Harbin Pharmaceutical Details
2.12.2 Harbin Pharmaceutical Major Business
2.12.3 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
2.12.4 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Amoytop Biotech
2.13.1 Amoytop Biotech Details
2.13.2 Amoytop Biotech Major Business
2.13.3 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Product and Services
2.13.4 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Jiuyuan Gene Engineering
2.14.1 Jiuyuan Gene Engineering Details
2.14.2 Jiuyuan Gene Engineering Major Business
2.14.3 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Product and Services
2.14.4 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Four Rings Biopharmaceutical
2.15.1 Four Rings Biopharmaceutical Details
2.15.2 Four Rings Biopharmaceutical Major Business
2.15.3 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
2.15.4 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Human Granulocyte Colony-stimulating Factor Breakdown Data by Manufacturer
3.1 Global Human Granulocyte Colony-stimulating Factor Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Human Granulocyte Colony-stimulating Factor
3.4 Market Concentration Rate
3.4.1 Top 3 Human Granulocyte Colony-stimulating Factor Manufacturer Market Share in 2021
3.4.2 Top 6 Human Granulocyte Colony-stimulating Factor Manufacturer Market Share in 2021
3.5 Global Human Granulocyte Colony-stimulating Factor Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Human Granulocyte Colony-stimulating Factor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Human Granulocyte Colony-stimulating Factor Market Size by Region
4.1.1 Global Human Granulocyte Colony-stimulating Factor Sales in Volume by Region (2017-2028)
4.1.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Region (2017-2028)
4.2 North America Human Granulocyte Colony-stimulating Factor Revenue (2017-2028)
4.3 Europe Human Granulocyte Colony-stimulating Factor Revenue (2017-2028)
4.4 Asia-Pacific Human Granulocyte Colony-stimulating Factor Revenue (2017-2028)
4.5 South America Human Granulocyte Colony-stimulating Factor Revenue (2017-2028)
4.6 Middle East and Africa Human Granulocyte Colony-stimulating Factor Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Human Granulocyte Colony-stimulating Factor Sales in Volume by Type (2017-2028)
5.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Type (2017-2028)
5.3 Global Human Granulocyte Colony-stimulating Factor Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Human Granulocyte Colony-stimulating Factor Sales in Volume by Application (2017-2028)
6.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Application (2017-2028)
6.3 Global Human Granulocyte Colony-stimulating Factor Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2028)
7.2 North America Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2028)
7.3 North America Human Granulocyte Colony-stimulating Factor Market Size by Country
7.3.1 North America Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2017-2028)
7.3.2 North America Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2028)
8.2 Europe Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2028)
8.3 Europe Human Granulocyte Colony-stimulating Factor Market Size by Country
8.3.1 Europe Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2017-2028)
8.3.2 Europe Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2028)
9.2 Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2028)
9.3 Asia-Pacific Human Granulocyte Colony-stimulating Factor Market Size by Region
9.3.1 Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2028)
10.2 South America Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2028)
10.3 South America Human Granulocyte Colony-stimulating Factor Market Size by Country
10.3.1 South America Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2017-2028)
10.3.2 South America Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2028)
11.2 Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2028)
11.3 Middle East & Africa Human Granulocyte Colony-stimulating Factor Market Size by Country
11.3.1 Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Human Granulocyte Colony-stimulating Factor and Key Manufacturers
12.2 Manufacturing Costs Percentage of Human Granulocyte Colony-stimulating Factor
12.3 Human Granulocyte Colony-stimulating Factor Production Process
12.4 Human Granulocyte Colony-stimulating Factor Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Human Granulocyte Colony-stimulating Factor Typical Distributors
13.3 Human Granulocyte Colony-stimulating Factor Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Human Granulocyte Colony-stimulating Factor Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Human Granulocyte Colony-stimulating Factor Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Chugai Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 4. Chugai Pharmaceutical Major Business
Table 5. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
Table 6. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Kyowa Hakko Kirin Basic Information, Manufacturing Base and Competitors
Table 8. Kyowa Hakko Kirin Major Business
Table 9. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Product and Services
Table 10. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Sanway Basic Information, Manufacturing Base and Competitors
Table 12. Sanway Major Business
Table 13. Sanway Human Granulocyte Colony-stimulating Factor Product and Services
Table 14. Sanway Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. GenSci Basic Information, Manufacturing Base and Competitors
Table 16. GenSci Major Business
Table 17. GenSci Human Granulocyte Colony-stimulating Factor Product and Services
Table 18. GenSci Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. SL PHARM Basic Information, Manufacturing Base and Competitors
Table 20. SL PHARM Major Business
Table 21. SL PHARM Human Granulocyte Colony-stimulating Factor Product and Services
Table 22. SL PHARM Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Kexing Bioproducts Basic Information, Manufacturing Base and Competitors
Table 24. Kexing Bioproducts Major Business
Table 25. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Product and Services
Table 26. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 28. Qilu Pharmaceutical Major Business
Table 29. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
Table 30. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. CSPC Basic Information, Manufacturing Base and Competitors
Table 32. CSPC Major Business
Table 33. CSPC Human Granulocyte Colony-stimulating Factor Product and Services
Table 34. CSPC Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Wuzhong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 36. Wuzhong Pharmaceutical Major Business
Table 37. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
Table 38. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Quangang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 40. Quangang Pharmaceutical Major Business
Table 41. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
Table 42. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Huabei Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 44. Huabei Pharmaceutical Major Business
Table 45. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
Table 46. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Harbin Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 48. Harbin Pharmaceutical Major Business
Table 49. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
Table 50. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Amoytop Biotech Basic Information, Manufacturing Base and Competitors
Table 52. Amoytop Biotech Major Business
Table 53. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Product and Services
Table 54. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Jiuyuan Gene Engineering Basic Information, Manufacturing Base and Competitors
Table 56. Jiuyuan Gene Engineering Major Business
Table 57. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Product and Services
Table 58. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Four Rings Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 60. Four Rings Biopharmaceutical Major Business
Table 61. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Product and Services
Table 62. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 63. Global Human Granulocyte Colony-stimulating Factor Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 64. Global Human Granulocyte Colony-stimulating Factor Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 65. Market Position of Manufacturers in Human Granulocyte Colony-stimulating Factor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 66. Global Human Granulocyte Colony-stimulating Factor Production Capacity by Company, (K Units): 2020 VS 2021
Table 67. Head Office and Human Granulocyte Colony-stimulating Factor Production Site of Key Manufacturer
Table 68. Human Granulocyte Colony-stimulating Factor New Entrant and Capacity Expansion Plans
Table 69. Human Granulocyte Colony-stimulating Factor Mergers & Acquisitions in the Past Five Years
Table 70. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2017-2022) & (K Units)
Table 71. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2023-2028) & (K Units)
Table 72. Global Human Granulocyte Colony-stimulating Factor Revenue by Region (2017-2022) & (USD Million)
Table 73. Global Human Granulocyte Colony-stimulating Factor Revenue by Region (2023-2028) & (USD Million)
Table 74. Global Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2022) & (K Units)
Table 75. Global Human Granulocyte Colony-stimulating Factor Sales by Type (2023-2028) & (K Units)
Table 76. Global Human Granulocyte Colony-stimulating Factor Revenue by Type (2017-2022) & (USD Million)
Table 77. Global Human Granulocyte Colony-stimulating Factor Revenue by Type (2023-2028) & (USD Million)
Table 78. Global Human Granulocyte Colony-stimulating Factor Price by Type (2017-2022) & (US$/Unit)
Table 79. Global Human Granulocyte Colony-stimulating Factor Price by Type (2023-2028) & (US$/Unit)
Table 80. Global Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2022) & (K Units)
Table 81. Global Human Granulocyte Colony-stimulating Factor Sales by Application (2023-2028) & (K Units)
Table 82. Global Human Granulocyte Colony-stimulating Factor Revenue by Application (2017-2022) & (USD Million)
Table 83. Global Human Granulocyte Colony-stimulating Factor Revenue by Application (2023-2028) & (USD Million)
Table 84. Global Human Granulocyte Colony-stimulating Factor Price by Application (2017-2022) & (US$/Unit)
Table 85. Global Human Granulocyte Colony-stimulating Factor Price by Application (2023-2028) & (US$/Unit)
Table 86. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2017-2022) & (K Units)
Table 87. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2023-2028) & (K Units)
Table 88. North America Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2022) & (USD Million)
Table 89. North America Human Granulocyte Colony-stimulating Factor Revenue by Country (2023-2028) & (USD Million)
Table 90. North America Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2022) & (K Units)
Table 91. North America Human Granulocyte Colony-stimulating Factor Sales by Type (2023-2028) & (K Units)
Table 92. North America Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2022) & (K Units)
Table 93. North America Human Granulocyte Colony-stimulating Factor Sales by Application (2023-2028) & (K Units)
Table 94. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2017-2022) & (K Units)
Table 95. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2023-2028) & (K Units)
Table 96. Europe Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2022) & (USD Million)
Table 97. Europe Human Granulocyte Colony-stimulating Factor Revenue by Country (2023-2028) & (USD Million)
Table 98. Europe Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2022) & (K Units)
Table 99. Europe Human Granulocyte Colony-stimulating Factor Sales by Type (2023-2028) & (K Units)
Table 100. Europe Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2022) & (K Units)
Table 101. Europe Human Granulocyte Colony-stimulating Factor Sales by Application (2023-2028) & (K Units)
Table 102. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2017-2022) & (K Units)
Table 103. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2023-2028) & (K Units)
Table 104. Asia-Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region (2017-2022) & (USD Million)
Table 105. Asia-Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region (2023-2028) & (USD Million)
Table 106. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2022) & (K Units)
Table 107. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Type (2023-2028) & (K Units)
Table 108. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2022) & (K Units)
Table 109. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales by Application (2023-2028) & (K Units)
Table 110. South America Human Granulocyte Colony-stimulating Factor Sales by Country (2017-2022) & (K Units)
Table 111. South America Human Granulocyte Colony-stimulating Factor Sales by Country (2023-2028) & (K Units)
Table 112. South America Human Granulocyte Colony-stimulating Factor Revenue by Country (2017-2022) & (USD Million)
Table 113. South America Human Granulocyte Colony-stimulating Factor Revenue by Country (2023-2028) & (USD Million)
Table 114. South America Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2022) & (K Units)
Table 115. South America Human Granulocyte Colony-stimulating Factor Sales by Type (2023-2028) & (K Units)
Table 116. South America Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2022) & (K Units)
Table 117. South America Human Granulocyte Colony-stimulating Factor Sales by Application (2023-2028) & (K Units)
Table 118. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales by Region (2017-2022) & (K Units)
Table 119. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales by Region (2023-2028) & (K Units)
Table 120. Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue by Region (2017-2022) & (USD Million)
Table 121. Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue by Region (2023-2028) & (USD Million)
Table 122. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales by Type (2017-2022) & (K Units)
Table 123. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales by Type (2023-2028) & (K Units)
Table 124. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales by Application (2017-2022) & (K Units)
Table 125. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales by Application (2023-2028) & (K Units)
Table 126. Human Granulocyte Colony-stimulating Factor Raw Material
Table 127. Key Manufacturers of Human Granulocyte Colony-stimulating Factor Raw Materials
Table 128. Direct Channel Pros & Cons
Table 129. Indirect Channel Pros & Cons
Table 130. Human Granulocyte Colony-stimulating Factor Typical Distributors
Table 131. Human Granulocyte Colony-stimulating Factor Typical Customers
List of Figures
Figure 1. Human Granulocyte Colony-stimulating Factor Picture
Figure 2. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Type in 2021
Figure 3. 300μg/Dose
Figure 4. 150μg/Dose
Figure 5. 75μg/Dose
Figure 6. Others
Figure 7. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Application in 2021
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Global Human Granulocyte Colony-stimulating Factor Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 11. Global Human Granulocyte Colony-stimulating Factor Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Human Granulocyte Colony-stimulating Factor Sales (2017-2028) & (K Units)
Figure 13. Global Human Granulocyte Colony-stimulating Factor Price (2017-2028) & (US$/Unit)
Figure 14. Global Human Granulocyte Colony-stimulating Factor Production Capacity (2017-2028) & (K Units)
Figure 15. Global Human Granulocyte Colony-stimulating Factor Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Human Granulocyte Colony-stimulating Factor Market Drivers
Figure 17. Human Granulocyte Colony-stimulating Factor Market Restraints
Figure 18. Human Granulocyte Colony-stimulating Factor Market Trends
Figure 19. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Manufacturer in 2021
Figure 20. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Manufacturer in 2021
Figure 21. Human Granulocyte Colony-stimulating Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Human Granulocyte Colony-stimulating Factor Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Human Granulocyte Colony-stimulating Factor Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2017-2028)
Figure 25. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2017-2028)
Figure 26. North America Human Granulocyte Colony-stimulating Factor Revenue (2017-2028) & (USD Million)
Figure 27. Europe Human Granulocyte Colony-stimulating Factor Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Human Granulocyte Colony-stimulating Factor Revenue (2017-2028) & (USD Million)
Figure 29. South America Human Granulocyte Colony-stimulating Factor Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue (2017-2028) & (USD Million)
Figure 31. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2017-2028)
Figure 32. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Type (2017-2028)
Figure 33. Global Human Granulocyte Colony-stimulating Factor Price by Type (2017-2028) & (US$/Unit)
Figure 34. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2017-2028)
Figure 35. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Application (2017-2028)
Figure 36. Global Human Granulocyte Colony-stimulating Factor Price by Application (2017-2028) & (US$/Unit)
Figure 37. North America Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2017-2028)
Figure 38. North America Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2017-2028)
Figure 39. North America Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2017-2028)
Figure 40. North America Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2017-2028)
Figure 41. United States Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2017-2028)
Figure 45. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2017-2028)
Figure 46. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2017-2028)
Figure 47. Europe Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2017-2028)
Figure 48. Germany Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2017-2028)
Figure 57. China Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2017-2028)
Figure 64. South America Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2017-2028)
Figure 65. South America Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2017-2028)
Figure 66. South America Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Human Granulocyte Colony-stimulating Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Human Granulocyte Colony-stimulating Factor in 2021
Figure 78. Manufacturing Process Analysis of Human Granulocyte Colony-stimulating Factor
Figure 79. Human Granulocyte Colony-stimulating Factor Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source